ATE388707T1 - Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen - Google Patents

Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen

Info

Publication number
ATE388707T1
ATE388707T1 AT00932162T AT00932162T ATE388707T1 AT E388707 T1 ATE388707 T1 AT E388707T1 AT 00932162 T AT00932162 T AT 00932162T AT 00932162 T AT00932162 T AT 00932162T AT E388707 T1 ATE388707 T1 AT E388707T1
Authority
AT
Austria
Prior art keywords
tramadol
bimodally
analgesic
opioid agonist
acting opioid
Prior art date
Application number
AT00932162T
Other languages
English (en)
Inventor
Stanley Crain
Ke-Fei Shen
Barry Sherman
Mary Remien
Remi Barbier
Nadav Friedmann
Original Assignee
Pain Therapeutics Inc
Einstein Coll Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pain Therapeutics Inc, Einstein Coll Med filed Critical Pain Therapeutics Inc
Application granted granted Critical
Publication of ATE388707T1 publication Critical patent/ATE388707T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00932162T 1999-05-06 2000-05-05 Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen ATE388707T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/306,164 US20010006967A1 (en) 1992-09-21 1999-05-06 Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists

Publications (1)

Publication Number Publication Date
ATE388707T1 true ATE388707T1 (de) 2008-03-15

Family

ID=23184116

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00932162T ATE388707T1 (de) 1999-05-06 2000-05-05 Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen

Country Status (8)

Country Link
US (1) US20010006967A1 (de)
EP (1) EP1178803B1 (de)
JP (1) JP2002544160A (de)
AT (1) ATE388707T1 (de)
AU (1) AU782533B2 (de)
CA (1) CA2373348A1 (de)
DE (1) DE60038290D1 (de)
WO (1) WO2000067739A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2266564B1 (de) 1997-12-22 2013-03-13 Euro-Celtique S.A. Peroral zu verabreichende Arzneiform enthaltend eine Kombination von einem opioid Agonisten und einem opioid Antagonisten
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
ITMI20010907A1 (it) * 2001-05-02 2002-11-02 Valpharma Sa Impiego di antagonisti oppioidi per la prevenzione ed il controllo degli effetti collaterali prodotti dagli oppioidi
JP4522652B2 (ja) 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ， インコーポレイティド 乱用防止制御放出オピオイド投薬形態
CA2778114A1 (en) * 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
CA2454328C (en) 2001-07-18 2008-03-18 Christopher D. Breder Pharmaceutical combinations of oxycodone and naloxone
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
LT2425824T (lt) 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20070276024A1 (en) * 2003-10-09 2007-11-29 Inverseon , Inc. Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
AU2004279438A1 (en) * 2003-10-09 2005-04-21 Inverseon, Inc. Methods for treating diseases and conditions with inverse agonists
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
US7337005B2 (en) 2004-09-08 2008-02-26 Spinal Modulations, Inc. Methods for stimulating a nerve root ganglion
US20120277839A1 (en) 2004-09-08 2012-11-01 Kramer Jeffery M Selective stimulation to modulate the sympathetic nervous system
US9205261B2 (en) 2004-09-08 2015-12-08 The Board Of Trustees Of The Leland Stanford Junior University Neurostimulation methods and systems
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
JP2009533459A (ja) * 2006-04-14 2009-09-17 シャイア エルエルシー 共有結合する化合物の鎮痛作用の増強と、有害な副作用の減衰と、前記化合物の乱用の予防とのための組成物及び方法
EP1897543A1 (de) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine-Waffel zur Substitutionstherapie
AU2007329253B2 (en) 2006-12-06 2014-03-27 Spinal Modulation, Inc. Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels
WO2008070809A2 (en) 2006-12-06 2008-06-12 Spinal Modulation, Inc. Implantable flexible circuit leads and methods of use
US9427570B2 (en) 2006-12-06 2016-08-30 St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) Expandable stimulation leads and methods of use
US9044592B2 (en) 2007-01-29 2015-06-02 Spinal Modulation, Inc. Sutureless lead retention features
BRPI0807282A2 (pt) * 2007-02-12 2014-04-29 Dmi Biosciences Inc Tratamento de ejaculação precoce e disfunção erétil co-mórbidas
NZ579170A (en) 2007-02-12 2012-05-25 Dmi Biosciences Inc Reducing side effects of tramadol
WO2009106831A2 (en) 2008-02-28 2009-09-03 Syntropharma Limited Pharmaceutical composition
EP3202457B1 (de) 2008-10-27 2020-05-27 Spinal Modulation Inc. Selektive stimulationssysteme und signalparameter für medizinische zustände
HUE042105T2 (hu) 2009-03-10 2019-06-28 Euro Celtique Sa Oxikodont és naloxont tartalmazó azonnali hatóanyagleadású orális gyógyászati készítmények
CA2758459A1 (en) 2009-03-24 2010-10-30 Spinal Modulation, Inc. Pain management with stimulation subthreshold to paresthesia
WO2010132816A2 (en) 2009-05-15 2010-11-18 Spinal Modulation, Inc. Methods, systems and devices for neuromodulating spinal anatomy
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
CA2798961A1 (en) 2010-05-10 2011-11-17 Spinal Modulation, Inc. Methods, systems and devices for reducing migration
WO2012106548A2 (en) 2011-02-02 2012-08-09 Spinal Modulation, Inc. Devices, systems and methods for the targeted treatment of movement disorders
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
EP3024461B1 (de) 2013-07-23 2020-05-13 Euro-Celtique S.A. Kombination aus oxycodon und naloxon für die verwendung bei der behandlung von schmerzen bei patienten mit schmerzen und einer krankheit, die zur intestinaldysbiose und/oder erhöhung der gefahr bakterieller translokation führt
MX2021000908A (es) 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
MX2022008554A (es) 2020-01-10 2022-08-10 Trevi Therapeutics Inc Metodos de administracion de nalbufina.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2728240B2 (ja) * 1988-07-26 1998-03-18 ヘキスト薬品工業株式会社 ヒトプロテインｃ変異体及びその製造方法

Also Published As

Publication number Publication date
CA2373348A1 (en) 2000-11-16
EP1178803B1 (de) 2008-03-12
EP1178803A2 (de) 2002-02-13
WO2000067739A3 (en) 2001-01-25
JP2002544160A (ja) 2002-12-24
US20010006967A1 (en) 2001-07-05
DE60038290D1 (de) 2008-04-24
WO2000067739A2 (en) 2000-11-16
AU782533B2 (en) 2005-08-04
AU4992800A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
ATE388707T1 (de) Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen
EP1539234A4 (de) Verfahren zur prävention oder behandlung von zellmalignität durch verabreichung von cd2-antagonisten
ATE446751T1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
WO2001037785A3 (en) Novel methods and compositions involving opioids and antagonists thereof
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
ATE414515T1 (de) Medikamente zur gleichzeitigen erhöhung der analgetischen wirksamkeit und verminderung des abhängigkeitspotentials, die durch exogene und endogene opioidagonisten verursacht werden
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
PT1135153E (pt) Utilizacoes para antagonistas e agonistas de receptores eph para tratar desordens vasculares
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
MXPA05003501A (es) Metodos para tratamiento del dolor administrando un antagonista del factor de crecimiento del nervio y un analgesico opioide y composiciones que los contienen.
CO4410317A1 (es) Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos.
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
IL162616A0 (en) Tetrahydroquinoline analogues as muscarinic agonists
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2002043807A3 (en) Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
EA200001112A1 (ru) Безводные и моногидратные формы n- (3-этинилфениламино)-6,7- бис (2-метоксиэтокси)-4-хиназолинамина мезилата
MXPA03009595A (es) Uso de antagonistas del canal de sodio neuronal para control de ectoparasitos de animales homeotermicos.
WO2001085150A3 (en) Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists
EP1262196A3 (de) Kombination eines Inhibitoren der Monoaminwiederaufnahme und eines Opioidanatagonisten zur Verwendung in Alkoholismus und Alkoholsucht
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
WO2007056142A3 (en) Methods of preventing the serotonin syndrome and compositions for use therefor
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
EA200401137A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties